Trial Profile
A Postmarket Registry of the BioMatrix and BioMatrix Flex Drug Eluting Stents.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2019
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions
- Acronyms eBMX-PMR
- Sponsors Biosensors International Group
- 03 May 2019 Status changed from active, no longer recruiting to completed.
- 06 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2016 to 1 Apr 2015.
- 21 May 2013 New registry data were presented at EuroPCR 2013, according to a Biosensors International Group.